Research to take the first step to practical application of peptide vaccine therapy for oral cancer patients who can not treat
| Project/Area Number |
16K11725
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | Kumamoto University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
尾木 秀直 熊本大学, 大学院生命科学研究部(医), 助教 (10315426)
|
|---|
| Project Period (FY) |
2016-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 口腔がん / バイオマーカー / 免疫療法 / CTLエピトープ / 口腔癌 / ペプチドワクチン療法 / トランスレーショナルリサーチ / 口腔腫瘍 / 腫瘍免疫 |
|---|
| Outline of Final Research Achievements |
Two papers were published in the International Journal of Oncology for the purpose of searching and identifying biomarkers that can predict therapeutic effects and developing simple detection methods for them. We also found that the molecule we have published can be used as a marker to reflect the progress of oral cancer and can also be a target molecule for tumor immunotherapy. On the other hand, also regarding the purpose of establishing a more effective peptide vaccine therapy for advanced cancer patients by combining previously identified HLA class II restricted antigen peptides recognized by Th1 cells and CTL epitope peptides so far. Announced to Oncoimmunology.
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究は東京大学医科学研究所および熊本大学免疫識別学講座との緊密な共同研究の成果です。本研究の結果、病期の判断マーカーもなく、また治療の効果を判定するマーカーもない口腔癌において、病状や病期を客観的に判断することのできる手段を得ることができたと考える。ニボルマブに関しても効果判定や適用患者を投与前に区分することができるかもしれない。さらに、免疫療法の治療標的分子としても、口腔癌を克服できる一筋の光明になる可能性を秘めていると考えている。
|
Report
(4 results)
Research Products
(7 results)
-
-
-
-
[Journal Article] An oncofetal antigen, IMP-3-derived long peptides induce immune responses of both helper T cells and CTLs2016
Author(s)
M. Hirayama, Y. Tomita, A. Yuno, H. Tsukamoto, S. Sejju, Y. Imamura, M. A. Sayem, A. Irie, Y. Yoshitake, D. Fukuma, M. Shinohara, A. Hamada, H. Jono, E. Yuba, K. Kono, K. Yoshida, T. Tsunoda, H. Nakayama, Y. Nishimura
-
Journal Title
OncoImmunology
Volume: 5
Issue: 6
Pages: e1123368-e1123368
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
[Journal Article] Sentinel lymph node biopsy reduces the incidence of secondary neck metastasis in patients with oral squamous cell carcinoma.2016
Author(s)
Hiraki A, Fukuma D, Nagata M, Shiraishi S, Kawahara K, Matsuoka Y, Nakagawa Y, Yoshida R, Tanaka T, Yohitake Y, Shinohara M, Yamashita Y, Nakayama H.
-
Journal Title
Molecular and Clinical Oncology
Volume: 5
Issue: 1
Pages: 57-60
DOI
Related Report
Peer Reviewed
-
-
[Presentation] Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients with induced immune responses and a prolonged OS.2017
Author(s)
③Yoshihiro Yoshitake, Daiki Fukuma, Akira Yuno, Masatoshi Hirayama, Hideki Nakayama, Takuya Tanaka, Masashi Nagata, Kenta Kawahara, Yoshihiro Nakagawa, Ryoji Yoshida, Hidenao Ogi, Akimitsu Hiraki, Hirofumi Jono, Akinobu Hamada, Koji Yoshida, Takuya Tsunoda, Yasuharu Nishimura, Yusuke Nakamura, Masanori Shinohara
Organizer
European Society for Medical Oncology （ESMO）
Related Report
Int'l Joint Research
